Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92229ArticlesСтатьиResearch ArticleRol' beta2-agonistov dlitel'nogo deystviya v lechenii khronicheskoy obstruktivnoy bolezni legkikhРоль beta2-агонистов длительного действия в лечении хронической обструктивной болезни легкихAver'yanovA. VАверьяновА. ВНИИ пульмонологии Росздрава, Москва15102006810VOL 8, NO10 (2006)ТОМ 8, №10 (2006)505428122021Copyright ©; 2006, Consilium MedicumCopyright ©; 2006, ООО "Консилиум Медикум"2006Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/92229

Главным условием терапии хронической обструктивной болезни легких (ХОБЛ) на всех стадиях заболевания является назначение бронхолитиков, не только облегчающих главный симптом – одышку, но и влияющих на ряд звеньев патогенеза. На сегодняшний день существует 3 основные группы бронхолитических препаратов: антихолинергические средства, b2-агонисты короткого и длительного действия и теофиллины.b2-Агонисты длительного действия (БАДД) – относительно новое поколение бронходилататоров. К их числу относятся зарегистрированные в Российской Федерации сальметерол и формотерол. В настоящее время БАДД рассматриваются в качестве препаратов первой линии для постоянной поддерживающей терапии стабильной ХОБЛ, начиная со II стадии заболевания

хроническая обструктивная болезнь легкихбронхолитикиформотеролP. J. Barnes R. A. Stockley COPD: current therapeutic interventions and future approaches Eur Respir J 2005; 25:1084–1106Zuwallack R.L, Mahler D.A, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661–1670Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; Update of the Management Section, GOLD website (www.goldcopd.com). Date update: September, 2005.O'Donnell D.E, Revill S.M, Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770–777.D. E. O'Donnell Is Sustained Pharmacologic Lung Volume Reduction Now Possible in COPD? Chest, March 1, 2006; 129(3): 501– 503.Cazzola, M, Matera, M.G, Santangelo, G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose - response study. Respir Med 1995; 89: 357–362.Cazzola, M, Santangelo, G, Piccolo, A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7; 103–107Aalbers, R, Ayres, J, Backer, V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19,936–943.Celik, G, Kayacan, O, Beder, S, et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo - controlled comparison of onset and duration of action. Respiration 1999; 66: 434–439Yan, K, Salome, C.M, Woolcock, A.J Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 132: 25–29Tashkin, D.P, Altose, M.D, Bleeker, E.R, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992; 145; 301–310Tashkin D.P, Altose M.D, Connett J.E, Kanner R.E, Lee W.W, Wise R.A. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease: the Lung Health Study Research Group. Am J Respir Crit Care Med 1996;153:1802–1811.Johnson P.R, Rudiger J.J, King G.G,et al. Lancet. 2002 Oct 26;360(9342):1293–9Harris, T, Koutsoubos, V, Guida, E, et al. Salmeterol modulates cell proliferation and cyclin D1 protein levels in thrombin - stimulated human cultured airway smooth muscle via an action independent of the b2-adrenoceptor [abstract]. Am J Respir Crit Care Med 1999; 159: A530.Szefler, S.J, Edwards, C.K, Haslett, C, et al. Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte b - adrenergic receptors. Biochem Pharmacol 1987; 36: 1589–97Zimmerman, G.A, Mc Intyre, T.M. Neutrophil adherence to human endothelium in vitro occurs by CD18 glycoprotein - dependent and - independent mechanisms. J Clin Invest 1988; 81: 531–37.Bowden, J.J, Sulakvelidze, I, Mc Donald, D.M. Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by b2-adrenergic agonist, formoterol. J Appl Physiol 1994; 77: 397–05Bolton, P.B, Lefevre, P, Mc Donald, D.M. Salmeterol reduces early - and late - phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155: 1428–35.Radermecker, M.F, Louis, R, Corhay, J.L, et al. Effect of salmeterol, theophylline and nedocromil sodium on neutrophil chemotaxis in man. Allergy 1992; 47,48Lee, E, Smith, J, Robertson, T, et al. Salmeterol and inhibitors of phosphodiesterase 4 (PDE-4) induce apoptosis in neutrophils from asthmatics: b - adrenergic receptor - mediated salmeterol activity and additive effects with PDE4 inhibitors. Am J Respir Cell Mol Biol 1999; 159: A329Ward, C, Li, X, Wang, N, et al. Salmeterol reduces BAL IL-8 levels in asthmatics on low dose inhaled corticosteroids. Eur Respir J 1998; 28: 380SReid, D.W, Ward, C, Wang, N, et al. Possible anti - inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003;21,994–99Maneechotesuwan K, Essilfie-Quaye S, Meah S, Kelly C, Kharitonov S.A, Adcock I.M, Barnes P.J Formoterol attenuates neutrophilic airway inflammation in asthma Chest. 2005 Oct;128(4):1936–42Anderson, P, Lotvall, J, Linden, A Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro. Lung 1996;174,159–70Murphy, T.F, Sethi, S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83Dowling R.B, Rayner C.F, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997;155:327–336Dowling R.B, Johnson M, Cole P.J, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998;11:86–90Rusznak, C, Sapsford, R.J, Devalia, J.L, et al. Influence of albuterol and salmeterol on ciliary beat frequency of cultured human bronchial epithelial cells. Thorax 1991; 46; 782PDevalia, J.L, Sapsford, R.J, Rusznak, C, et al. The effects of salmeterol and albuterol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulm Pharmacol 1992; 5: 257–63Melloni, B, Germouty, J. The influence of a new b agonist: formoterol on mucociliary function. Rev Mal Respir 1992; 9; 503–7Kanthakumar, K, Cundell, D.R, Johnson, M, et al. Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin. Br J Pharmacol 1994; 112: 493–98Jones, P.W, Bosh, T.K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155; 1283–89Ramirez-Venegas, A, Ward, J, Lentine, T, et al. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112; 336–40Goldkorn A, Diotto P, Burgess C, et al. The pulmonary and extra - pulmonary effects of high - dose formoterol in COPD: a comparison with salbutamol. Respirology 2004;9:102–108Campbell M, Eliraz A, Johansson G et al. Formoterol for maintenance and as - needed treatment of chronic obstructive pulmonary disease Respir Med. 2005 Dec;99(12):1511–20Cazzola M, Santus P, Matera M.G, et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 2003;97:458–462Rennard, S.I, Anderson, W, Zuwallack, R, et al. Use of a long - acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163,1087–92.Dahl, R, Greefhorst, L.A, Nowak, D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164,778–84.Taccola, M, Bancalari, L, Ghignoni, G, et al. Salmeterol versus slow - release theophylline in patients with reversible obstructive pulmonary disease. Monaldi Arch Chest Dis 1999; 54; 302–06Di Lorenzo, G, Morici, G, Drago, A, et al. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild - to - moderate chronic obstructive pulmonary disease: SLMT02 Italian Study Group. Clin Ther 1998; 20: 1130–48Brusasco, V, Hodder, R, Miravitlles, M, et al. Health outcomes in a 6-month placebo controlled trial of once - daily tiotropium compared with twice - daily salmeterol in patients with COPD. Thorax 2003;58,399–404Chapman, K.R, Arvidsson, P, Chuchalin, A.G, et al. The addition of salmeterol 50 µg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002;9,178–185Mahler D.A, Donohue J.F, Barbee R.A, Goldman M.D, Gross N.J, Wisniewski M.E, Yancey S.W, Zakes B.A, Rickard K.A, Anderson W.H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–965.Van Noord, J.A, de Munck, D.R.A.J, Bantje, T, et al. Long - term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15,878–85Rossi, A, Kristufek, P, Levine, B.E, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow - release theophylline in the treatment of COPD. Chest 2002;121,1058–69Szafranski, W, Cukier, A, Ramirez, A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease. Eur Respir J 2003;21,74–81Pikaar, J.C, Voorhout, W.F, van Golde, L.M, et al. Opsonic activities of surfactant proteins A and D in phagocytosis of Gram - negative bacteria by alveolar macrophages. J Infect Dis 1995; 172; 481–489Hartshorn K.L, White M.R, Shepherd et al.: Mechanism of anti - influenza activity of surfactant proteins A and D. Am J Phisiol 1997: 273: 1156–1166.Lusuardi, M, Capelli, A, Carli, S, et al. Role of surfactant in chronic obstructive pulmonary disease: therapeutic implications. Respiration 1992; 59(suppl 1),28–32.Mason R.J, Murray J.F, Broaddus V.C, Nadel J.A Textbook of respiratory medicine (4-th ed.) 2005, Elsevier Inc, Vol. 1, P 303.Kumar, V, Kresch, M. Effects of salmeterol (S) on phosphatidylcholine (PC) secretion by type II cells. Pediatr Res 1996; 39:337A.Sichletidis L, Kottakis J, Marcou S, Constantinidis T.C, Antoniades A. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999;53:185–188Zuwallack R.L, Mahler D.A, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661–1670.Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449–456Hanania N.A, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834–843Denis E. O’Donnell, M.D; Frank Sciurba, M.D; Bartolome Celli Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD Chest. 2006;130:647–656Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, Matera M.G. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004;98:1214–1221Jan A. van Noord, M.D, Ph.D, F.C.C.P; Joseph L. Aumann, M.D; Eduard Janssens, M.D Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest. 2006;129:509–517.Salpeter S.R, Ormiston T.M, Salpeter E.E. Cardiovascular effects of b - agonists in patients with asthma and COPD: a meta - analysis. Chest 2004;125:2309–2321Sovani M.P, Whale C.I, Tattersfield A.E. A benefit - risk assessment of inhaled long - acting b2-agonists in the management of obstructive pulmonary disease. Drug Safety 2004;27:689–715.Rosenkranz B, Rouzier R, Kruse M, et al. Safety and tolerability of high - dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease Respir Med. 2006 Apr;100(4):666–72Цой А.Н., Архипов В.В. Формотерол и обострения бронхиальной астмы. Consilium medicum, 2006, т.8, №3 стр. 58–61